Leucovorin News
Stop-and-Go Oxaliplatin Effective in Elderly Colon Cancer Patients
Elderly patients with metastatic colon cancer, those between 76 and 80 years of age, have response and survival rates similar to their younger counterparts when given a treatment approach that includes stop-and-go oxaliplatin.
More cancer patients to be treated with Eloxatin(R) following Health Canada's approval of new indication
Health Canada has approved Eloxatin(R) (oxaliplatin for injection), in combination with infusional 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFOX4), for the adjuvant (post-surgical) treatment of patients with stage III colon...
Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors
Erlotinib (Tarceva) is a potent epidermal growth factor receptor (HER1) inhibitor. Infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) is a standard therapy for colorectal cancer. This trial assessed the...
Two cases of multiple liver metastases from colorectal cancer which responded well to hepatic arterial infusion (HAI) using 5-fluorouracil and l-leucovorin
We present two cases of multiple liver metastases from colorectal cancer, which did not respond to hepatic arterial infusion (HAI) using 5-fluorouracil (5-FU 1250 mg/body weekly) alone, but responded to HAI using 5-fluorouracil...
Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma
Conventional chemotherapy for urothelial carcinoma, such as methotrexate, vinblastine, doxorubicin and cisplatin, is associated with significant toxicity. We have previously reported a low toxicity and yet moderately active...